Minerva Neurosciences (NASDAQ:NERV – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday.
Separately, HC Wainwright decreased their price target on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating on the stock in a research note on Thursday, May 2nd.
Read Our Latest Stock Report on Minerva Neurosciences
Minerva Neurosciences Stock Performance
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.07. As a group, analysts forecast that Minerva Neurosciences will post -1.89 EPS for the current fiscal year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Read More
- Five stocks we like better than Minerva Neurosciences
- What Investors Need to Know About Upcoming IPOs
- Roblox: The Bottom Just Fell Out of the Metaverse
- 3 Fintech Stocks With Good 2021 Prospects
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- 3 Warren Buffett Stocks to Buy Now
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.